11-47346298-G-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.999C>G(p.Tyr333Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Y333Y) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000256.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.999C>G | p.Tyr333Ter | stop_gained | 12/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.999C>G | p.Tyr333Ter | stop_gained | 12/35 | 5 | NM_000256.3 | ENSP00000442795 | P4 | |
MYBPC3 | ENST00000399249.6 | c.999C>G | p.Tyr333Ter | stop_gained | 11/34 | 5 | ENSP00000382193 | A2 | ||
MYBPC3 | ENST00000544791.1 | c.999C>G | p.Tyr333Ter | stop_gained, NMD_transcript_variant | 12/27 | 5 | ENSP00000444259 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 29, 2015 | The p.Tyr333X variant in MYBPC3 has been reported in 3 individuals with HCM, seg regated with disease in 1 affected relative from 1 family (Kassem 2013, LMM unpu blished data) and was absent from large population studies. This nonsense varian t leads to a premature termination codon at position 333, which is predicted to lead to a truncated protein. Heterozygous loss of function of the MYBPC3 gene is an established disease mechanism in HCM. In summary, this variant meets our cri teria to be classified as pathogenic for HCM in an autosomal dominant manner. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 30, 2023 | This sequence change creates a premature translational stop signal (p.Tyr333*) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 23233322, 25351510, 25611685). ClinVar contains an entry for this variant (Variation ID: 177706). For these reasons, this variant has been classified as Pathogenic. - |
Cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Oct 28, 2022 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 10, 2023 | Reported in ClinVar as a pathogenic variant (ClinVar Variant ID# 177706; ClinVar); Not observed in large population cohorts (gnomAD); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 31006259, 25611685, 27532257) - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 09, 2013 | The p.Y333X pathogenic mutation, located in coding exon 12 of the MYBPC3 gene, results from a C to G substitution at nucleotide position 999. This changes the amino acid from a tyrposine to a stop codon within coding exon 12. This alteration was identifed in 1 of 192 unrelated Egyptians with a clinical diagnosis of hypertrophic cardiomyopathy (Kassem Hsh etal. J Cardiovasc Transl Res. 2013;6:65-80). Futhermore, haploinsufficiency of MYBPC3 has been indicated as a mechanism of disease, causing hypertrophic cardiomyopathy (Marston et al. 2012 J Muscle Res Cell Motil 33:75-80). In addition to the data presented in the literature, premature stop codons are typically deleterious in nature and interpreted as disease-causing mutations (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med 2008;10:294). Based on the supporting evidence, p.Y333X is interpreted as a pathogenic mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at